Fedovapagon

Drug Profile

Fedovapagon

Alternative Names: VA-106483; VA483

Latest Information Update: 07 Apr 2016

Price : $50

At a glance

  • Originator Vantia Therapeutics
  • Class Antidiuretics; Small molecules
  • Mechanism of Action Vasopressin V2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Nocturia

Most Recent Events

  • 01 Mar 2016 Phase-II/III clinical trials in Nocturia in USA (PO)(NCT02637960)
  • 28 Dec 2015 Vantia plans the phase II/III EQUINOC trial for Nocturia (in patients with benign prostatic hyperplasia) in USA (PO) (NCT02637960)
  • 03 Oct 2015 No recent reports of development identified - Phase-I/II for Nocturia (In the elderly) in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top